Journal article
Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial
Abstract
BACKGROUND: Heart failure (HF) patients with atrial fibrillation (AF) often have conduction system disorders, which may be worsened by β-blocker therapy.
OBJECTIVE: In a post hoc analysis we examined the prevalence of bradycardia and its association with adverse events (AEs) and failure to achieve target dose in the GENETIC-AF trial.
Authors
Abraham WT; Piccini JP; Dufton C; Carroll IA; Healey JS; O’Connor CM; Marshall D; Aleong R; van Veldhuisen DJ; Rienstra M
Journal
Heart Rhythm O2, Vol. 3, No. 1, pp. 40–49
Publisher
Elsevier
Publication Date
February 2022
DOI
10.1016/j.hroo.2021.11.005
ISSN
2666-5018